Explore Antibody Drug Conjugates
Combining the selectivity of monoclonal antibodies with potent cytotoxic agents
Antibody drug conjugate (ADC) technology leverages the selectivity of monoclonal antibodies (MAbs) to offer new possibilities to cancer patients.1 This approach has been approved in the management of select hematologic malignancies and solid tumors.1,2
ADCs can be an effective and targeted vehicle designed to deliver potent cytotoxic agents directly to tumor cells through selective antibody binding.3
ADCs are a rational vehicle to exploit the internalization of CD79b for the delivery of a potent cytotoxic agent inside target cells.3,4
This technology may be applied as foundational ADC therapy or as a
potential complement to existing treatment approaches.1
Genentech is a leader in developing therapeutic MAbs and next-generation MAb-based platforms, including ADCs.5 Genentech is currently investigating the potential of using an ADC with other agents, such as traditional monoclonal antibodies, PD-L1 inhibitors, small molecules, and T-cell bispecific antibodies.5,6
- Diamantis N, Banerji U. Br J Cancer. 2016;114:362-367. PMID: 26742008
- Pfeifer M, Zheng B, Erdmann T, et al. Leukemia. 2015;29:1578-1586. PMID: 25708834
- Peters C, Brown S. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432
- Polson AG, Yu S-F, Elkins K, et al. Blood. 2007;110:616-623. PMID: 17374736.
- Roche first-quarter results 2019 presentation. https://www.roche.com/dam/jcr:f03df0f2-852c-47a5-9924-343bfb239c37/en/irp190417.pdf. Accessed April 18, 2019.
- US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671018. Published September 14, 2018. Updated October 1, 2018. Accessed October 22, 2018.